Johnson & Johnson (NYSE:JNJ) Shares Sold by Asset Advisors Investment Management LLC

Asset Advisors Investment Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 109,932 shares of the company's stock after selling 11,676 shares during the period. Johnson & Johnson makes up approximately 1.9% of Asset Advisors Investment Management LLC's holdings, making the stock its 19th largest holding. Asset Advisors Investment Management LLC's holdings in Johnson & Johnson were worth $17,816,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. ERn Financial LLC raised its position in Johnson & Johnson by 2.9% during the 2nd quarter. ERn Financial LLC now owns 7,221 shares of the company's stock valued at $1,055,000 after purchasing an additional 202 shares during the last quarter. Mcdonald Partners LLC boosted its holdings in Johnson & Johnson by 2.3% in the second quarter. Mcdonald Partners LLC now owns 26,481 shares of the company's stock valued at $3,871,000 after acquiring an additional 585 shares in the last quarter. Comprehensive Financial Consultants Institutional Inc. increased its position in Johnson & Johnson by 16.1% during the 2nd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 26,377 shares of the company's stock valued at $3,855,000 after purchasing an additional 3,666 shares during the period. Home Federal Bank of Tennessee raised its holdings in Johnson & Johnson by 0.7% in the 2nd quarter. Home Federal Bank of Tennessee now owns 17,608 shares of the company's stock worth $2,574,000 after purchasing an additional 119 shares in the last quarter. Finally, Hunter Perkins Capital Management LLC boosted its stake in shares of Johnson & Johnson by 16.6% during the 2nd quarter. Hunter Perkins Capital Management LLC now owns 101,655 shares of the company's stock valued at $14,858,000 after purchasing an additional 14,456 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.3 %

JNJ stock traded up $0.38 during trading on Friday, hitting $146.62. The company had a trading volume of 8,292,995 shares, compared to its average volume of 7,123,573. The firm has a market capitalization of $353.01 billion, a P/E ratio of 21.16, a PEG ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a 50 day simple moving average of $157.01 and a 200-day simple moving average of $156.28.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.66 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on JNJ shares. Bank of America restated a "neutral" rating and issued a $166.00 target price on shares of Johnson & Johnson in a research note on Tuesday. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Finally, Wells Fargo & Company boosted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus price target of $174.73.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.